Physician profile
Antonio T Uvas
NPI 1730109745
$2,614.05
in general payments reported to CMS, 2019-2025
19 companies · $859 in 2025
The $859 reported for 2025 was more than what 83% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $409 · 2020: $42.22 · 2021: $15.55 · 2023: $357 · 2024: $931 · 2025: $859.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,147.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,147.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,689.59 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $201.90 | 2019-2025 | Rybelsus, Ozempic |
| Amgen INC. | $159.42 | 2024-2025 | Otezla, Repatha |
| Intuitive Surgical, INC. | $79.73 | 2024 | |
| Corcept Therapeutics | $73.71 | 2023-2024 | Korlym |
| Novartis Pharmaceuticals Corporation | $54.17 | 2020-2025 | |
| Abbott Laboratories | $40.70 | 2019 | |
| Merck Sharp & Dohme LLC | $38.05 | 2019-2024 | Vaxneuvance, M-M-R II, Gardasil 9 |
| Dexcom, INC. | $37.82 | 2024-2025 | Dexcom G6 Transmitter |
| Glaxosmithkline, LLC. | $31.05 | 2019-2023 | Shingrix, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $30.50 | 2023-2024 | Jardiance |
| Nestle Healthcare Nutrition INC. | $30.09 | 2021-2023 | |
| Inspire Medical Systems, INC. | $27.56 | 2024 | Inspire |
| Abiomed | $22.76 | 2025 | |
| Edwards Lifesciences Corporation | $22.50 | 2025 | Sapien 3 Ultra Resilia |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $21.75 | 2025 | Nexlizet, Nexletol |
| Janssen Pharmaceuticals, INC | $18.55 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $18.39 | 2025 | |
| Eisai INC. | $15.81 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Antonio Uvas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.